The P-II trial evaluates the safety, tolerability & effect of PTR-01 on wound healing along with other EPs in patients with RDEB
The results showed ≥50% reduction in wound surface area @120 Days over 80% of target wounds while clinician assessment of the same target lesions showed a similar level of efficacy & wound improvement, 15 out of 26 wounds (58%) met the response criteria of ≥2-point increase on the wound-specific scale at 15 days after initiating treatment, 69% met the response criteria, 67% were responders @120 Day, was well-tolerated over 4mos. treatment period
Improvement in PROs, all patients who completed the study reported a pain reduction, 36% mean reduction in total pain from the end of the study
Ref: Bridgebio | Image: Bridgebio
